[Hiring] Director, Strategic Pricing @Revolution Medicines

Role Description

Revolution Medicines is seeking a Director, US Strategic Pricing, to develop and lead brand and portfolio strategic net pricing recommendations to include:

• Pricing and contract research
• Advanced analytics
• Contract design recommendations
• Gross-to-net forecasting to inform net price strategies

The Director will oversee provider contracting strategy, including engagements with:

• Group Purchasing Organizations (GPOs)
• Integrated Delivery Networks (IDNs)
• Integrated health systems
• Government customers

Responsibilities include:

• Evaluating contract structures
• Assessing provider economics
• Ensuring contracting approaches align with site-of-care, reimbursement, and policy considerations
• Developing and delivering executive-level pricing and contracting materials for Quarterly Business Reviews (QBRs)
• Clearly communicating pricing strategies, financial implications, and key decision considerations to senior leadership

This role can be based in Redwood City, CA, or can be remotely based with up to 15% travel.

Qualifications

• Bachelor’s degree
• 10+ years of pharmaceutical market access experience
• 4+ years of Oncology product experience
• 6+ years of pricing and payer/provider contracting experience
• Extensive experience in customer segment contract strategy, market knowledge, and pricing policies
• Strong understanding of IRA policy guidelines and CMS price demonstrations
• Experience with day-to-day management of vendor partners
• Strong knowledge of trends, issues, and policies influencing drug pricing and oncology market
• Ability to communicate effectively, both orally and in writing
• Ability to deliver strategy and price recommendations to various audience types
• Embrace cross-functional collaboration with internal and external customers
• Ability to effectively resolve conflicts and align multiple departments

Requirements

• Experience with oral oncology therapies and targeted treatments for RAS-mutated cancers (preferred)
• Advanced degree (MBA, MPH, or similar) (preferred)

Benefits

• Competitive cash compensation
• Robust equity awards
• Strong benefits
• Significant learning and development opportunities

Company Description

Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins.

The company’s RAS(ON) inhibitors currently in clinical development include:

• Daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor
• Elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor
• Zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor
• RMC-5127, a RAS(ON) G12V-selective inhibitor

As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway.